Inhibrx Biosciences has reported positive interim data from the Phase II segment of its HexAgon study assessing INBRX-106 in treatment-naïve, PD-L1 positive metastatic or unresectable recurrent HNSCC. The post Inhibrx announces positive interim results from HexAgon trial appeared first on Hospital Management.
Inhibrx Biosciences has reported positive interim data from the Phase II segment of its HexAgon study assessing INBRX-106 in treatment-naïve, PD-L1 positive metastatic or unresectable recurrent HNSCC.The post Inhibrx announces positive interim results from HexAgon trial appeared first on Hospital Management.
